



BELEAVE ANNOUNCES THE ADDITION OF FORMER DRUG PROSECUTOR CHRIS MURPHY TO THE TEAM

Toronto, ON – June 15th 2016 – Beleave Inc. (CSE: BE) (“Beleave” or the “Company”) is pleased to announce that Chris Murphy B.A., M.A., LL.B. will be added to the company’s Advisory Board.

Chris Murphy is a Toronto-based regulatory and criminal lawyer. He sits on the board of directors of Star Produce Ltd., one of Canada’s largest distributors of fresh fruit and vegetables with more than 100 offshore programs and 200,000 square feet of refrigerated distribution space.

Mr. Murphy will bring to Beleave a wealth of experience in logistics, food safety, greenhouse operations, and information systems capable of tracking product from seed to sale.

“We are most pleased to welcome Chris to our Advisory Board and anticipate his involvement to grow within the company as we endeavour to advance through the licensing process and into production. Chris has broad experience and industry connections with greenhouses, distribution networks and retailers across North America, we welcome him on board as an invaluable asset that will assist in all areas of our business from production practices, expansion plans to sales.” said Beleave CEO Roger Ferreira.

Mr. Murphy is a former drug prosecutor with the Department of Justice Canada. Before becoming a prosecutor, he acted as a judicial law clerk at the Supreme Court of British Columbia. Mr. Murphy also practiced civil litigation at a firm of some 150 lawyers in Calgary, Alberta. In addition, he served as a special constable with the Royal Canadian Mounted Police.

Mr. Murphy received a Bachelor of Laws with Distinction in 2000. In 1997, he obtained a Master of Arts degree. He had previously graduated with a Bachelor of Arts Degree with High Honours in 1994. In 2004, he received a Certificate in International Criminal Law from Salzburg Law School, and in 2015 he graduated from the Directors Education Program at the University of Toronto’s Rotman School of Management.

About Beleave

Beleave Inc. is a biotech company committed to becoming a licensed producer under the *Marihuana for Medical Purposes Regulations* (the "**MMPR**"). Beleave's wholly owned subsidiary First Access Medical Inc. ("**FAM**") has applied for a licence to cultivate and sell medical marihuana pursuant to the MMPR. As of the date hereof, FAM has successfully advanced past the security clearance stage and is currently in the review stage of the licensing process.

Beleave's purpose built facility is located near Hamilton, Ontario. Beleave is traded on the CSE under the symbol BE, with 17,380,823 common shares outstanding (25,541,826 on a fully diluted basis).

For more information contact:

Sebastian de Kloet

Phone: 1 (905) 979 - 5173

Email: Sebastian@beleave.com

www.beleave.com

Cautionary Statements Regarding Forward-Looking Information

Certain statements within this press release relating to the Company constitute “forward-looking statements”, within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and / or objectives, sales programs, forecasts and projections, assumptions, expectations, and/or beliefs of future performance, are "forward-looking statements". Such "forward-looking statements" involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including production and / or sales of medical marijuana, quantities of future medical marijuana production, anticipated revenues in connection with such sales, the overall projected size of the market, completion and / or expansion of production facilities, and other information that is based on forecasts of future results, estimates of production not yet determinable, and other key management assumptions. Actual results may differ materially from those expressed or implied by such forward-looking statements and involve risk and uncertainties relating to the Company's historical experience with medical marijuana operations, regulatory changes, timeliness of government approvals for the granting of permits and licenses, changes in medical marijuana prices, actual operating performance of facilities, and other uninsured risks. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Further, there can be no assurance that Beleave’s medical marijuana license application will be approved by Health Canada, or that any prospective projects in the industry will be successfully completed.